Anavex Life Sciences
AVXL
62 hedge funds and large institutions have $41.5M invested in Anavex Life Sciences in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 5 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 13
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
2% more funds holding
Funds holding: 61 → 62 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.08% less ownership
Funds ownership: 24.88% → 23.8% (-1.1%)
24% less capital invested
Capital invested by funds: $54.7M → $41.5M (-$13.2M)
87% less call options, than puts
Call options by funds: $593K | Put options by funds: $4.65M
Top Buyers
| 1 |
BlackRock
New York
|
+$404K |
| 2 |
SFG
SNS Financial Group
Minneapolis,
Minnesota
|
+$311K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$266K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$172K |
| 5 |
VF
Virtu Financial
New York
|
+$110K |
Top Sellers
AVXL Hedge Fund Activity: Q3 2017 in Review
62 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q3 2017, worth a combined $41.5M — down 24% from $54.7M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new AVXL positions and 5 closed out — a net gain of 2 holders — while 22 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $404K. The largest seller was Park West Asset Management, cutting an estimated $1.91M.
- 62 institutional investors held Anavex Life Sciences (AVXL) as of Q3 2017, up from 61 in Q2 2017.
- Funds reported $41.5M of Anavex Life Sciences stock for Q3 2017, down 24% quarter-over-quarter.
- 7 funds opened new Anavex Life Sciences positions in Q3 2017 and 5 closed out, a net change of +2 holders.
- The largest Anavex Life Sciences buyer in Q3 2017 was BlackRock, an estimated $404K added.
- The largest Anavex Life Sciences seller in Q3 2017 was Park West Asset Management, an estimated $1.91M sold.
Based on aggregated 13F filings for Q3 2017.